John Mascola | CSO
ModeX Therapeutics

John Mascola, CSO, ModeX Therapeutics

Dr. John Mascola is Chief Scientific Officer of ModeX Therapeutics, a company developing innovative multispecific immunotherapies for cancer and infectious disease. He is an accomplished physician-scientist, virologist and immunologist with over 25 years’ experience in research and development of vaccine and antibody therapeutics. Prior to joining ModeX, he was the Director of the Vaccine Research Center, NIAID, NIH where he oversaw the development of investigational products for major diseases such as HIV, Ebola, respiratory syncytial virus, chikungunya and malaria. Under his leadership, the VRC established collaborative partnerships leading to the licensure of therapeutic antibodies and vaccines for Ebola and COVID-19. Dr. Mascola has received numerous awards and recognitions, including the outstanding service medal from the U.S. Department of Health and Human Services. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the National Academy of Medicine.


Day 3 - Thursday 4th April @ 09:10

Development of a broadly reactive multispecific COVID antibody

last published: 26/Feb/24 13:16 GMT

back to speakers